Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Is Increased in Human Left Ventricle after Acute Myocardial Infarction

Archives of Medical Research

Volumn 40, Issue 7, 2009, Pages 605-611

  Nie, Ruqiong ^a   Xie, Shuanglun ^a   Du, Bin ^a   Liu, Xiaoyan ^b   Deng, Bingqing ^a   Wang, Jingfeng ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; EMMPRIN; Matrix metalloproteinase; Ventricular remodeling

Indexed keywords

CD147 ANTIGEN; GELATINASE A; GELATINASE B;

ACUTE HEART INFARCTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; ANTIGENS, CD147; FEMALE; HEART VENTRICLES; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 71649112891     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.09.001     Document Type: Article

References (34)

1. Pfeffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 (1990) 1161-1172
2. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87 (2007) 1285-1342
3. Vanhoutte D., Schellings M., Pinto Y., et al. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 69 (2006) 604-613
4. Lindsey M.L. MMP induction and inhibition in myocardial infarction. Heart Failure Rev 9 (2004) 7-19
5. Villarreal F.J., Griffin M., Omens J., et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108 (2003) 1487-1492
6. Hayashidani S., Tsutsui H., Ikeuchi M., et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285 (2003) H1229-H1235
7. Romanic A.M., Harrison S.M., Bao W., et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 54 (2002) 549-558
8. Ducharme A., Frantz S., Aikawa M., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
9. Matsusaka H., Ide T., Matsushima S., et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47 (2006) 711-717
10. Matsumura S., Iwanaga S., Mochizuki S., et al. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115 (2005) 599-609
11. Creemers E.E., Cleutjens J.P., Smits J.F., et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res 89 (2001) 201-210
12. Spinale F.G., Coker M.L., Thomas C.V., et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
13. Biswas C., Zhang Y., DeCastro R., et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55 (1995) 434-439
14. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
15. Siwik D.A., Kuster G.M., Brahmbhatt J.V., et al. EMMPRIN mediates beta-adrenergic receptor-stimulated matrix metalloproteinase activity in cardiac myocytes. J Mol Cell Cardiol 44 (2008) 210-217
16. Schmidt R., Bultmann A., Ungerer M., et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 113 (2006) 834-841
17. Levick S.P., and Brower G.L. Regulation of matrix metalloproteinases is at the heart of myocardial remodeling. Am J Physiol Heart Circ Physiol 295 (2008) H1375-H1376
18. Suzuki S., Sato M., Senoo H., et al. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 293 (2004) 259-266
19. Fielitz J., Leuschner M., Zurbrugg H.R., et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 82 (2004) 809-820
20. Zavadzkas J.A., Plyler R.A., Bouges S., et al. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol 295 (2008) H1394-H1402
21. Camp T.M., Tyagi S.C., Aru G.M., et al. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 23 (2004) 729-736
22. Tessone A., Feinberg M.S., Barbash I.M., et al. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 19 (2005) 383-390
23. Peterson J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 69 (2006) 677-687
24. Kawakami R., Saito Y., Kishimoto I., et al. Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 110 (2004) 3306-3312
25. Lu L., Zhang J.Q., Ramires F.J., et al. Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue. Biochem Biophys Res Commun 320 (2004) 907-913
26. Olivetti G., Capasso J.M., Sonnenblick E.H., et al. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Circ Res 67 (1990) 23-34
27. Romanic A.M., Burns-Kurtis C.L., Gout B., et al. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 68 (2001) 799-814
28. van den Borne S.W., Cleutjens J.P., Hanemaaijer R., et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 18 (2009) 37-43
29. Reinhardt D., Sigusch H.H., Hensse J., et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
30. Sakata Y., Yamamoto K., Mano T., et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109 (2004) 2143-2149
31. Gomez-Hernandez A., Sanchez-Galan E., Ortego M., et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am J Cardiol 102 (2008) 12-18
32. Furenes E.B., Arnesen H., Solheim S., et al. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res (2009)
33. Fiotti N., Altamura N., Orlando C., et al. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol 127 (2008) 350-357
34. Cevik C., Otahbachi M., Nugent K., et al. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization. J Cardiovasc Med (Hagerstown) 9 (2008) 1274-1278